Genprex to Present at the 11th Annual LD Micro Main Event
December 03 2018 - 8:30AM
Business Wire
Presentation Wed., Dec. 5, 2018, at 10:30
a.m. PST
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company developing a new approach to treating cancer based upon a
novel proprietary technology platform, announced today that its
Chairman and Chief Executive Officer, Rodney Varner, will present
at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard
Hotel in Los Angeles, CA.
Genprex is scheduled to present on Wed., Dec. 5, 2018, at 10:30
a.m. PST. Genprex management will also attend one-on-one meetings
with institutional investors throughout the day.
The LD Micro Main Event is the largest independent conference
for small/micro-cap companies and will feature 250 companies
presenting to an audience of over 1,200 attendees.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing a new approach to treating cancer, based upon a novel
proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex™ immunogene therapy for non-small cell
lung cancer (NSCLC). Genprex’s platform technologies are designed
to administer cancer fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then
administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at http://www.genprex.com or follow Genprex on Twitter at
https://twitter.com/genprex and Facebook at
https://www.facebook.com/genprexinc/.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into
several influential events annually (Invitational, Summit, and Main
Event). In 2015, LDM launched the first pure microcap index (the
LDMi) to exclusively provide intraday information on the entire
sector. LD will continue to provide valuable tools for the benefit
of everyone in the small and micro-cap universe.
For those interested in attending, please contact David Scher at
david@ldmicro.com or visit http://www.ldmicro.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181203005478/en/
Media:James HeinsICR
Healthcare203-682-8251James.Heins@icrinc.comInvestors:Stephanie
CarringtonICR
Healthcare646-277-1282Stephanie.Carrington@icrinc.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024